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Abstract: The sesquiterpene lactone thapsigargin is found in the plant Thapsia garganica L., 
and is one of the major constituents of the roots and fruits of this Mediterranean species.  
In 1978, the first pharmacological effects of thapsigargin were established and the full structure 
was elucidated in 1985. Shortly after, the overall mechanism of the Sarco-endoplasmic reticulum 
Ca2+-ATPase (SERCA) inhibition that leads to apoptosis was discovered. Thapsigargin has 
a potent antagonistic effect on the SERCA and is widely used to study Ca2+-signaling. The 
effect on SERCA has also been utilized in the treatment of solid tumors. A prodrug has been 
designed to target the blood vessels of cancer cells; the death of these blood vessels then 
leads to tumor necrosis. The first clinical trials of this drug were initiated in 2008, and the 
potent drug is expected to enter the market in the near future under the generic name 
Mipsagargin (G-202). This review will describe the discovery of the new drug, the on-going 
elucidation of the biosynthesis of thapsigargin in the plant and attempts to supply the global 
market with a novel potent anti-cancer drug. 
Keywords: thapsigargin; mipsagargin; Thapsia garganica; pharmacology; biosynthesis; 
traditional use; sesquiterpene lactone 
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1. The Genus Thapsia 
1.1. Traditional Use and Description 
Thapsia L. species, otherwise known as deadly carrots, have been used in traditional medicine in the 
Mediterranean region for thousands of years. Hippocrates and Theophrastus first described the  
skin-irritating effects and medicinal uses of Thapsia garganica L. around 300–400 BC. In 1597, the effect 
of Thapsia was vividly described as “if a man do stand where the wind doth blow from the plant, the air 
doth exulcerate and blister the face, and every other bare or naked place that may be subject to his 
venomous blast and poisonous quality” [1]. Although this description is an exaggeration, direct skin 
contact with the plant can result in dermatitis in the form of erythema, small blisters and itching. The 
resin from the roots and stems of T. garganica has been used as a remedy against a number of diseases 
and maladies: female sterility, pulmonary diseases, catarrh, fever, pneumonia and as a counter irritant 
for the relief of rheumatic pains [1–3]. In 1857 the use of T. garganica in Europe was recommended for 
the treatment of lung diseases, catarrh and rheumatic pains, through the application of a medicinal plaster 
containing the root resin [4]. In present day Morocco Thapsia spp. are still in use in traditional  
medicine [3,5]. Furthermore, T. garganica has been featured in several pharmacopoeias [6]. 
The effects of Thapsia spp. are due to the presence of specialized metabolites, such as sesquiterpenoids, 
which are found in all members of the genus [7]. In particular, the bioactivity of the sesquiterpenoid 
thapsigargin extracted from T. garganica has been thoroughly investigated. In 1978, for instance, it was 
shown that thapsigargin functions as a potent histamine liberator when tested on rat mast cells [8].  
In addition, the treatment of mammalian cells with thapsigargin was shown to result in raised calcium 
levels in the cytoplasm and in 1990 thapsigargin was established as an inhibitor of the  
sarco-endoplasmic reticulum Ca2+-ATPase (SERCA) [9].  
1.2. Phylogeny of Thapsia L. 
Thapsia is a small genus of herbaceous perennials in the Apiaceae family that is widely distributed 
across the Mediterranean from Portugal and Morocco to Greece and Turkey. The most extensively 
distributed species within the genus is T. garganica [10,11]. Thapsia species have characteristic bright 
yellow flowers, four-winged seeds, large umbels and stems that can reach a height of up to two meters 
(Figure 1). The genus is currently poorly defined, with frequent errors in species identification or conflicting 
views on which names define which members of the group. This is especially problematic in the case of 
users of traditional medicine, where the selection of the wrong plant can lead to the intoxication of 
patients. In Morocco, for example, where women use the root of what should be Thapsia villosa L. in 
preparations against sterility or to gain weight, cases of vomiting and violent diarrhea have been reported [2], 
likely due to the use of morphologically similar species. Based on the most recent phylogenetic analysis 
of Thapsia, the genus includes 14 species [10]. Chemotaxonomic revisions, however, are still ongoing 
and frequently reveal new intra- or interspecies relationships [12].  
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Figure 1. Show the yellow inflorescence of Thapsia garganica, and the mature infructescence 
of the species. Photos by Karen Martinez. 
1.3. Sesquiterpenoids in Thapsia 
Sesquiterpenoids are widespread within the genus Thapsia, however, it is thapsigargin and the group 
of similar compounds, guaianolides, which are of most interest (Table 1). Due to the toxicity of thapsigargin 
towards mammals, one in planta function is expected to be protection of the plants from herbivory. 
Thapsigargin has only been reported in T. garganica [13] and T. gymnesica Rosselló and Pujadas [7]. 
The concentration of thapsigargin varies even within species, seemingly dependent of its locality [13]. 
Wild plants of T. garganica have a concentration of thapsigargin of 0.2%–1.2% of the dry weight of the 
roots and 0.7%–1.5% of the dry weight of the ripe fruits, whilst the dried stems and leaves contain a total 
concentration of 0.1%–0.5% and 0.1% respectively [13].  
Table 1. Thapsigargin and similar guaianolides reported within Thapsia. The table is amended 
from Drew et al. [14] The top sketch illustrates the core structure of thapsigargin.  
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Table 1. Cont. 
Species Compound R1 R2 Reference 
T. garganica L. 
Thapsigargin  [8] 
Thapsigargicin O
O O
 [8] 
Thapsivillosin C-E See below  [15] 
Thapsivillosin I O
O
O
 [13] 
Thapsivillosin J O
O O
 [13] 
Thapsivillosin L O
O O
 [16] 
Nortrilobolid H  [17] 
Trilobolid H 
O
 
[13,17] 
not named O
O
H [18] 
not named O
O
H [18] 
T. gymnesica Rosselló 
& A. Pujadas 
Thapsigargin See above  [7] 
Thapsigargicin See above  [7] 
Nortrilobolid See above  [7] 
T. villosa L. 
Thapsivillosin A O
O O
 
[19] 
Thapsivillosin B O
O O
 
[13] 
Thapsivillosin C O
O
 
O
 
[13] 
Thapsivillosin D O
O O
 
[13] 
Thapsivillosin E O
O O
 
[13] 
Thapsivillosin F H 
O
 
[13] 
Thapsivillosin G O
O O
 
[13] 
Thapsivillosin H 
O
O
 or 
OH
O
 
Exact positions undefined 
[13] 
O
O O
O
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Table 1. Cont. 
Species Compound R1 R2 Reference 
T. villosa L. 
Thapsivillosin K O
O
 
O
 
[13] 
Thapsitranstagin O
O
 
O
 
[13,20] 
Trilobolide See above  [19] 
T. transtagana Brot. 
Thapsitranstagin O
O
 
O
 
[13,21] 
Thapsivillosin B See above  [13,21] 
Trilobolid See above  [13,21] 
Thapsivillosin K See above  [13,21] 
T. smittii Simonsen, 
Rønsted, Weitzel and 
Spalik 
Thapsivillosin A, B, H See above  [19] 
2. Thapsigargin and Guaianolide Biosynthesis in Thapsia 
Terpenoids are the largest class of small natural products and are structurally highly diverse, containing 
metabolites of both general and specialized metabolism [22]. Within the terpenoids, sesquiterpenoids (C15) 
are a large group of specialized metabolites. Thapsigargin is a sesquiterpene lactone and belongs to the 
subgroup guaianolides. This group has a guaiene backbone and a lactone ring (see Table 1). 
2.1. The Biosynthesis of Sesquiterpene Lactones 
Sesquiterpenoids are built from isopentenyl diphosphate (IPP) and dimethylally diphosphate (DMAPP), 
which are small molecules consisting of five carbon atoms. IPP and DMAPP, which are used for 
sesquiterpenoid and sterol biosynthesis, are biosynthesized by the mevalonate (MVA) pathway located 
in the cytosol. Similar to many other anabolic pathways, acetyl-CoA is used as the starting material  
and NADPH as an energy source [22]. The second pathway for biosynthesis of IPP and DMAPP is the 
methylerythritol phosphate (MEP) pathway found in the plastids [23,24]. The MEP pathway generates 
precursors for carotenoids, chlorophylls, monoterpenoids, and diterpenoids [25,26]. Cross talk has been 
observed between the two pathways, and studies with labeled precursors in Daucus carota L., have revealed 
the presence of a unidirectional proton symport of IPP from plastids to the cytoplasm in several higher 
plants [26–29].  
In the cytosol, IPP and DMAPP are fused to synthesize the sesquiterpenoid precursor farnesyl 
diphosphate (FPP) by farnesyl diphosphate synthase. FPP can undergo several possible cyclization reactions 
that lead to more than 300 cyclic sesquiterpene skeletons [22]. The cyclizations begin with the isomerization 
of FPP that leads to a wide variety of mono, di or tricyclic structural elements. These backbone structures 
then frequently undergo secondary modifications, often by cytochromes P450 and acyl transferases to 
yield the huge diversity found within the chemical family of terpenoids [30].  
Artemisinin, produced by Artemisia annua L., is the best-characterized sesquiterpene lactone to date. 
Investigations include biosynthetic studies in microorganisms, Nicotiana and Artemisia  
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plants [31–33]. Other well studied sesquiterpene lactones include costunolide from Lactuca sativa L. 
(lettuce), which has been studied in Saccharomyces cerevisiae and Nicotiana [34]. Both artemisinin and 
costunolide (Figure 2) were identified in the Asteraceae family and, although they are not guaianolides like 
thapsigargin, many of the reactions required to generate these molecules are believed to be similar to 
those generating thapsigargin [35].  
O
O
O
O OH
H
H
O
O
Artemisinine Costunolide  
Figure 2. Structure of artemisinin and costunolide.  
2.2. Thapsigargin Biosynthesis 
No studies have yet been able to elucidate the biosynthetic pathway of guaianolides within the  
Apiaceae. Even the biosynthesis of the otherwise well-studied compound thapsigargin is unknown. Given 
the promising results of its use as an anti-cancer drug [36], the annual demand of thapsigargin is expected 
to increase [37]. This encourages the development of production protocols. One possibility is the 
biotechnological production in a gene modified organism; an approach that requires the detailed 
knowledge of the biosynthesis of thapsigargin [38,39]. 
A terpene synthase, TgTPS2, found in the transcriptome libraries (SRX096991, there is no genome 
sequence available) of T. garganica roots and fruits was found to convert FPP to kunzeaol. Kunzeaol is 
a probable candidate for the first biosynthetic step towards thapsigargin (Figure 3) [35]. The hydroxyl 
group at the C6 position of kunzeaol makes this a good substrate for the subsequent formation of the 
lactone ring. The following steps are thought to be similar to the ones of costunolide biosynthesis whereby 
the formation of the lactone ring is followed by the guaiene skeleton formation [34,40]. The enzyme 
family cytochromes P450 are prime candidates to participate in lactone ring formation. A triple hydroxylation 
on C12, as seen in costunolide, would lead to the formation of an acid group which would perform a 
spontaneous reaction with the OH on C6 and form a lactone ring. Cytochromes P450 might also catalyze the 
formation of guaiene rings by an epoxidation of the C1-10 double bond; however, this is still to  
be elucidated. 
 
Figure 3. Suggested first step of the biosynthesis of thapsigargin via kunzeaol. 
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A number of hydroxylations are needed on positions C2, C3, C7, C8, C10 and C11, followed by the 
decoration of the core structure by the addition of acyl groups. Since most of the enzymes involved in 
this pathway are assumed to be cytochromes P450, sufficient oxygen and NADPH are crucial for the 
efficiency of the biosynthesis.  
3. Pharmacology of Thapsigargin 
Thapsigargin is structurally unique. The lactone ring is a trans-anealated C7α-C6β γ-ring, which also 
has trans hydroxyl groups at C7 and C11 [22]. Thapsigargin, like other sesquiterpenoid lactones in general, 
is known for its biological activity. The main and most important pharmacological activity of thapsigargin is 
its potent inhibition of the SERCA pump. This effect is significant in sub-nanomolar concentrations [9,41]. 
The irreversible inhibition of SERCA leads to elevated cytoplasmic Ca2+ levels that induce apoptosis. 
An X-ray structure of the thapsigargin-SERCA complex provided the foundation for understanding the 
structural conformation of the complex, as well as the surroundings of the binding site [42]. This additionally 
provided detailed information for the design of a targeted prodrug with thapsigargin as the active 
component [42]. The prodrug is designed so that it is only activated by cancer cells, leading to apoptosis 
in the tumor [43]. 
The affinity of thapsigargin to SERCA is mainly due to lipophilic interactions between the C2 
octanoyl, the C3 angeloyl-, and the C8 butanoyl-moieties and alpha-helices of SERCA. The interactions 
of the side-chains with SERCA have been confirmed using analogues without side-chains or inverted 
stereochemistry [42]. This has led to an in-depth understanding of the importance of the side-chains of 
thapsigargin [44]. Interestingly, when the ester group at C8 was changed from an α to a β configuration, 
the Ca2+-ATPase inhibiting properties of the molecule decreased 3000-fold [7]. Using X-ray it was 
shown that the C8 butanoyl group is situated in a cavity between helices when bound to the SERCA 
protein, a position that only allows an α configuration. It has also been shown that removing the angeloyl 
group or simply changing the stereochemistry of C3 leads to a significant decrease of the Ca2+-ATPase 
inhibitory effect [42]. Exchange of the acetyl group at C10 with a hydroxy moiety also decreases the 
biological activity of thapsigargin. Collectively, these findings show that within certain size limits, the 
localization of the side-chain is of more importance than its structure [16]. For the development of a 
prodrug, the discovery of the flexibility of the length and size of the acyl group linked to the C8-O was 
of great importance [42]. 
Since the effect of thapsigargin leads to apoptosis in any mammalian cell, thapsigargin is not suitable 
for use as an unmodified drug. This has been overcome by way of a prodrug strategy. The neovascular 
tissue of solid tumors generally, over-expresses the proteolytic enzyme Prostate Specific Membrane 
Antigen (PSMA). PSMA is a serine-protease that cleaves at specific amino acid motifs. Utilizing the 
flexibility at C8 in thapsigargin, a linker-peptide moiety that is recognized by PSMA has been attached 
to thapsigargin. The prodrug with the linker-peptide moiety is inactive towards the SERCA pump, but 
upon cleavage of the peptide moiety by PSMA the molecule becomes lipophilic and toxic. The lipophilic 
properties of the drug allow it to enter into the cellular membranes where it can interact with SERCA [44]. 
The activated drug, even with the small linker molecule, will then inhibit SERCA, which leads to 
apoptosis [45]. The prodrug was tested in vivo in nude mice, with xenografts from a human prostate cancer 
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cell line [46]. It was observed that the level of cleaved active drug was much higher in tumor tissue than 
in the plasma or skeletal muscle of the mice, confirming effective drug targeting [47]. 
GenSpera (San Antonio, TX, USA), the company developing thapsigargin, holds several patents that 
cover the use of anti-cancer prodrugs that can be activated by tumors via the use of Tumor Activated 
Prodrug technology [48–50]. Initially, development was focused on treating prostate cancer by using 
thapsigargin coupled to a prostate specific peptide, resulting in the drug G-115 [37]. However, the design 
of a peptide cleaved by PSMA, which is expressed by most solid tumors expanded the use substantially 
and has led to the development of G-202 [43,44,51]. The difference between G-115 and G-202 is  
in the peptide sequences that are linked to thapsigargin. For G115 this is (starting from thapsigargin) 
Leu-Gln-Leu-Lys-Ser-Ser-His-Morpholine, and for G-202 it is Asp-Glu-Glu-Glu-Glu. In G-115 the PSA 
enzyme cleaves after the first leucine, whereas in G-202 PSMA cleaves after the first glutamic acid [43]. 
Focus has been shifted towards developing G-202, since this will also cover prostate cancer. Further 
clinical trials with G-115 are postponed, as GenSpera focuses on human trials with G-202 on patients with 
various types of cancer. Following the success of phase I clinical trials, the prodrug G-202 is now in phase II 
clinical trials for patients suffering from hepatocellular cancer (HCC) [43]. In phase I it was demonstrated 
that the drug was safe and well tolerated in patients with advanced stages of HCC and prolonged disease 
stabilization was observed [51]. G-202 or Mipsagargin is expected to be launched on the market in the 
coming years [37]. 
4. Production Platforms for Thapsigargin 
The demand of thapsigargin is increasing given its potential medical application as a chemotherapeutic 
prodrug [37]. Currently, all of the commercially available thapsigargin is obtained from the fruits and 
roots of wild populations of T. garganica [52,53]. The demand for thapsigargin is expected to exceed 
the levels of current production, which may lead to a high harvest pressure that could endanger the 
species [52,54]. Therefore, one of the major challenges will be to establish new production platforms to 
meet the potential market demand for thapsigargin. 
4.1. Agricultural Production 
Cultivation of Thapsia has been shown to be complicated. T. garganica is difficult to germinate from 
seeds and to maintain under greenhouse conditions [52,54]. With successful germination, handling of 
the seedlings has to be done with care, since the roots are very fragile. ThapsIbiza, a Spanish company 
based on Ibiza has started a small production of T. garganica plants. Recently a method for the extraction 
of large quantities of thapsigargin was published enabling large scale production [55].  
4.2. Organ Cultures for Thapsigargin Production 
Micropropagation provides an alternative source for the production of thapsigargin [56]. Jäger et al. 
reported the establishment of T. garganica in in vitro cultures, for the purpose of producing  
thapsigargin [54]. Calli and suspension cultures of T. garganica were induced and underwent treatments 
with different elicitors, without successful production of thapsigargin [52]. The fact that thapsigargin is 
found in the resin present in specific secretory canals in the plant, may indicate the necessity of 
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differentiation for the synthesis and storage of the bioactive compound [6]. Consequently, somatic 
embryos were induced and accumulated the two guaianolides, nortrilobolid and trilobolid, in the 
cotyledonary stage [54].  
The formation of shoots directly from petiole and leaflet explants has also been studied [52]. A 60% 
rooting frequency was noted after 10 days when roots were submerged in MS liquid medium with plant 
growth regulator [56]. The ability to initiate prolific root formation may be advantageous [52], since 
roots have the ability to produce thapsigargin [57]. Hence, transgenic hairy roots are potentially an alternative 
source for this purpose [58].  
4.3. Production in Heterologous Hosts 
A variety of heterologous hosts may be suitable for large-scale production of thapsigargin or precursors 
thereof. Saccharomyces cerevisiae (yeast) is one option inspired by the efforts on the production of 
artemisinin. Several modifications using yeast are well described for high terpenoid production e.g., 
overexpression of up-stream terpenoid specific genes [32]. The green cell production system of the moss 
Physcomitrella patens has likewise been shown to be a promising producer of both sesquiterpenoids and 
diterpenoids [59,60], and could serve well as a production host for thapsigargin [38,39]. P. patens has 
several advantages since it can be grown in sterile cultures [39] and on a simple liquid or solid inorganic 
medium without phytohormones, vitamins or a carbon source [61]. Furthermore, P. patens performs 
homologous recombination with high efficiency [62], enabling the development of a stable production 
strain that does not require crossing steps or regeneration of whole plants [63]. The main obstacle, regardless 
of the choice of host organism, is the discovery of the thapsigargin biosynthetic genes. 
4.4. Chemical Synthesis of Thapsigargin 
The biological activity of thapsigargin makes it a viable drug candidate and this has led to efforts  
to chemically synthesize it and numerous analogues [36,45,64–68]. Despite the successful synthesis of 
thapsigargin, as well as other bioactive compounds with complex chemical structures, a commercially 
feasible synthetic route to these high value compounds remains a challenge. In 2004, attempts to prepare 
the guaianolide skeleton of thapsigargin commenced and in 2007 the first total synthesis of thapsigargin 
was reported [69,70]. The approach allowed for the total synthesis of thapsigargin in 42 steps from  
(s)-carvone with an overall yield of 0.6% [70]. The weakness of this method is the lack of a strategy for 
obtaining the core of the structure in a few steps and the cost of the initial starting material.  
Alternative methods include synthesizing 7,11-dihydroxyguaianolide, an intermediate in the 
synthesis of thapsigargin, in six steps starting from (+)-dihydrocarvone and ethyl vinyl ketone [71].  
7,11-dihydroxyguaianolide possesses five of the eight chiral centers present in thapsigargin and 
additionally allows for simple modifications of the C2 and C8 positions [71]. In 2012, Tap et al. 
developed the functionalized bicycledecadienone ring system of thapsigargin through a Pauson-Khand 
annulation reaction, however, the lactone ring and the oxygen atom on the C8 carbon atom were not 
incorporated [72].  
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5. Conclusions 
Focus on the production of the upcoming drug thapsigargin will continue. The latest developments 
suggest that the future need will be met by plant tissue cultures along with the plants being cultivated on 
Ibiza. Approaches utilizing semi-synthesis or total synthesis are currently far from being economically 
feasible. Nonetheless, future research might provide new strategies for such approaches and open up for 
an extended use of thapsigargin. New prodrugs are currently being developed towards certain cancer types, 
and as a whole, the use of thapsigargin as a drug and chemical compound will increase in the next decade. 
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